Fact-checked by Grok 2 weeks ago

Echinococcus multilocularis

Echinococcus multilocularis is a zoonotic cestode parasite, commonly known as the fox tapeworm, that causes alveolar (AE), a chronic, tumor-like liver infection in humans and other accidental hosts. The adult worm measures 1.2–4.5 mm in length and resides in the of definitive hosts, primarily wild canids such as red . In its larval stage, it forms multi-chambered cysts that infiltrate tissues, mimicking and leading to high mortality if untreated. The life cycle of E. multilocularis is indirect and sylvatic, involving definitive hosts like foxes, , wolves, and occasionally , which harbor the adult worms and excrete infective eggs in their feces. Intermediate hosts, mainly of the Arvicolinae (such as voles and lemmings), ingest these eggs, which hatch into oncospheres that penetrate the intestinal wall and develop into metacestode cysts, predominantly in the liver. The cycle completes when a definitive host consumes an infected intermediate host, allowing the larvae to mature into adults in the intestine. Humans become infected accidentally by ingesting eggs contaminated on , , or environments frequented by infected canids, but they are dead-end hosts as the cysts do not produce eggs. Epidemiologically, E. multilocularis is endemic to the , with high-prevalence regions in , northern Asia (particularly and ), and parts of . It contributes significantly to the global burden of , affecting over 1 million people worldwide and causing approximately 19,300 deaths and 871,000 disability-adjusted life years (DALYs) annually across all Echinococcus species. Incidence rates vary, but in highly endemic areas like parts of , they reach up to 6 cases per 100,000 population, with the parasite emerging in new regions due to ecological changes and wildlife population dynamics. Risk factors include rural residence, contact with foxes or , and consumption of unwashed produce in endemic zones. Clinically, AE often remains asymptomatic for 5–15 years before manifesting with nonspecific symptoms such as , , , and due to progressive liver involvement. The disease progresses invasively, with cysts capable of to distant organs like the lungs, , or , resulting in organ failure and a fatality rate approaching 90–100% without intervention. Diagnosis relies on (e.g., ultrasonography or showing characteristic multilocular lesions), serologic tests (with >95% sensitivity using antigens like Em2), and sometimes . Treatment typically involves radical surgical resection combined with long-term anti-parasitic therapy, such as , though complete cure is challenging and often requires lifelong management. Prevention strategies emphasize domestic dogs and cats, environmental , and targeted anthelmintic baiting for wild foxes, as population culling has proven ineffective.

Biology

Taxonomy

_Echinococcus multilocularis is classified within the domain Eukaryota, kingdom Animalia, phylum Platyhelminthes, class , subclass , order , family Taeniidae, genus , and species multilocularis. This positioning places it among the tapeworms, characterized by their ribbon-like bodies and complex life cycles involving multiple hosts. The genus name Echinococcus derives from the Greek words echinos (meaning "" or "spiny"), referring to the hook-bearing scolex, and kokkos (meaning ""), alluding to the fluid-filled, berry-like appearance of the larval cysts. The specific epithet multilocularis originates from Latin roots multi- (many) and locularis (compartmentalized or chambered), describing the multi-chambered, alveolar structure of its metacestode stage, which contrasts with the unilocular cysts of related species like E. granulosus. The species was first described by German parasitologist Rudolf Leuckart in 1863, based on metacestodes from a case in , marking it as distinct from E. granulosus, which produces single-chambered hydatid . This description resolved early taxonomic debates, confirming E. multilocularis as a separate entity within the , with its alveolar morphology as a key differentiating feature. Modern taxonomy relies on molecular markers, particularly (mtDNA) sequences such as subunit 1 (cox1) and dehydrogenase subunit 1 (nad1), to differentiate E. multilocularis from other Echinococcus species and detect intraspecific . These markers have supported phylogenetic analyses, affirming its close relation to the E. granulosus complex while highlighting its unique evolutionary lineage.

Morphology

Echinococcus multilocularis exhibits distinct morphological features across its life stages, adapted to its complex involving definitive and intermediate hosts. The adult worm is a slender tapeworm, typically measuring 1.2 to 4.5 mm in length, with a maximum of up to 7 mm reported in some cases. It comprises a scolex with four acetabular suckers and a rostellum armed with two rows of 25 to 50 hooks, a short neck, and three to five proglottids: an immature proglottid, one or more mature proglottids containing hermaphroditic reproductive organs (including 16 to 35 testes, a cirrus sac, branched ovaries, and vitellary glands), and a terminal gravid proglottid with a branched filled with eggs. The gravid proglottid is characteristically longer than wide and constitutes less than 50% of the worm's total length. The eggs of E. multilocularis are taeniid-type, round structures measuring 30 to 40 μm in diameter, released individually from the disintegrating gravid proglottids into the of the definitive . Each is enclosed in a thick, radially striated embryophore and contains a hexacanth with three pairs of hooklets, enabling penetration of the intermediate 's intestinal wall upon ingestion. The larval or metacestode stage develops as multilocular alveolar cysts, forming a polycystic mass of aggregated microvesicles that can grow from millimeters to several centimeters or more, lacking a defined capsule and exhibiting exogenous budding for proliferation. These cysts feature an outer acellular laminated layer and an inner nucleated germinal layer, from which brood capsules bud inward to produce protoscolices; each protoscolex mirrors the adult scolex with four suckers and a hooked rostellum, often invaginated into a posterior body. Microscopically, the metacestodes present as infiltrating vesicular structures in tissues, particularly the liver, with the laminated layer showing positive staining with periodic acid-Schiff () and protoscolices displaying hooklets under hematoxylin-eosin or trichrome stains.

Life cycle

Echinococcus multilocularis maintains a zoonotic life cycle primarily involving definitive and intermediate hosts, with humans serving as accidental dead-end hosts. The definitive hosts are carnivores, predominantly wild canids such as red foxes (Vulpes vulpes), coyotes ( latrans), and wolves ( lupus), as well as domestic (Canis familiaris) and, to a lesser extent, (Felis catus) and raccoon dogs (Nyctereutes procyonoides). In these hosts, the adult tapeworm, measuring 1.2–4.5 mm in length, resides in the , where it matures and produces gravid proglottids containing infectious eggs that are shed in feces. The intermediate hosts are typically small rodents, including voles (e.g., Microtus arvalis and Microtus oeconomus), lemmings, mice, , and occasionally other small mammals such as pikas in certain regions (e.g., the ). When an intermediate host ingests eggs from contaminated vegetation, soil, or water, the eggs hatch in the , releasing six-hooked oncospheres that penetrate the intestinal mucosa. These oncospheres then migrate via the or , primarily to the liver, where they develop into multilocular alveolar hydatid cysts characterized by infiltrating, tumor-like growth. The cysts contain protoscolices that can develop into adult worms if ingested by a definitive host, completing the cycle through predation. In definitive hosts, the prepatent period—from ingestion of protoscolices to the production of eggs—ranges from 28 to 35 days, though it can extend to 32–80 days depending on the host and intensity. In intermediate hosts, the cysts grow slowly over months to years, enabling long-term persistence. Humans become infected as accidental intermediate hosts through the fecal-oral route, typically by ingesting eggs from contaminated food, water, soil, or surfaces exposed to infected definitive host feces, such as during handling of or unwashed produce. Unlike in the natural , infections do not contribute to , as the cysts do not produce protoscolices capable of infecting other hosts. The eggs of E. multilocularis are immediately infectious upon release and exhibit high environmental resilience, remaining viable for up to 240 days in cool, moist autumn or winter conditions, but only about 78 days in warmer, drier summer environments. They tolerate freezing temperatures and low humidity better than heat or desiccation, facilitating survival in temperate soils and water sources for extended periods, often exceeding 12 months under optimal cool and moist conditions.

Alveolar echinococcosis

Pathogenesis

Upon ingestion of eggs containing oncospheres, Echinococcus multilocularis initiates infection in humans by hatching in the , where the oncospheres use enzymatic activity and secreted proteins to penetrate the intestinal mucosa and enter the portal and lymphatic circulation. These larvae primarily lodge in the liver, accounting for over 90% of cases, where they develop into infiltrating metacestodes that form multilocular cysts resembling malignant tumors due to their irregular, expansive growth without defined boundaries. The metacestodes grow through continuous of the germinal layer via exogenous , producing numerous small vesicles that infiltrate surrounding and compress ducts and vessels. This leads to localized ischemia, , and subsequent as the host responds to the ongoing destruction, creating a fibrotic capsule around the that further promotes the parasite's infiltrative expansion. The is sustained by the parasite's exploitation of nutrients and stimulation by factors such as insulin and hormones, enabling a slow but relentless progression that mimics . To evade host immunity, the cysts secrete immunomodulatory molecules including inhibitors (serpins), Kunitz-type inhibitors, and excretory/secretory products that induce a Th2- and Treg-dominated response, characterized by elevated IL-10 and TGF-β levels, which suppress effective Th1/Th17-mediated clearance and foster formation around the lesions. This allows persistent , with specific IgE responses observed but insufficient to eliminate the parasite. Additionally, fragments of the metacestode can disseminate hematogenously, leading to metastasis-like spread to distant sites such as the lungs or , establishing secondary lesions. The typically remains for 5–15 years during this indolent phase, with clinical manifestations emerging only upon significant or organ compromise.

Signs and symptoms

Alveolar echinococcosis often remains asymptomatic for many years, with an typically ranging from 5 to 15 years after initial infection, allowing the larval cysts to grow slowly in the liver without causing noticeable effects. When early symptoms do emerge, they are usually nonspecific and include mild upper , or weakness, and gradual , which may be attributed to the expanding hepatic lesions. These manifestations can mimic those of other chronic liver conditions, such as or , complicating initial recognition. As the disease advances, symptoms become more pronounced due to progressive liver involvement, including with or without a palpable mass in the right upper quadrant, and right epigastric pain. occurs rarely but may develop if biliary obstruction arises from compression or invasion of the bile ducts, potentially accompanied by signs of hepatic failure such as general . Extrahepatic spread, which happens in a subset of cases via direct extension or hematogenous dissemination, can lead to additional symptoms depending on the affected site; pulmonary involvement often presents with , , and , while central nervous system lesions may cause neurological deficits like seizures or headaches. Complications in advanced stages frequently include from vascular compression or thrombosis, biliary obstruction leading to , and secondary bacterial infections such as cholangitis due to invasion or rupture. The disease's tumor-like, infiltrative growth pattern contributes to these issues, often resulting in delayed diagnosis until the lesions are extensive and inoperable. Many cases are detected incidentally through performed for unrelated reasons, highlighting the insidious nature of the infection. Without intervention, alveolar echinococcosis progresses slowly over 10 to 20 years, with mortality exceeding 90% due to organ failure or complications.

Diagnosis

Diagnosis of alveolar echinococcosis (AE) caused by Echinococcus multilocularis typically involves a combination of , serological, and histopathological methods to confirm the presence of the larval stage in , often presenting as an infiltrative liver lesion mimicking . Ultrasonography serves as the initial screening tool due to its accessibility and ability to detect characteristic lesions, while advanced and laboratory tests provide definitive confirmation. Imaging plays a central role in visualizing the multilocular, infiltrative nature of AE lesions. is the technique of choice for primary detection, revealing hypoechoic areas with irregular borders, sometimes resembling a "hailstorm" pattern due to internal debris and calcifications; improves characterization of lesion vascularity. demonstrates solid, ill-defined hepatic masses with central and peripheral calcifications, often in a ring-like or plaque distribution, aiding in assessing lesion extent and involvement of adjacent structures. offers superior soft tissue contrast, highlighting hypointense lesions on T1-weighted images with hyperintense necrotic cores on T2-weighted sequences, and is particularly useful for evaluating biliary or vascular invasion. tomography-computed (PET-CT) using [18F]-fluorodeoxyglucose assesses metabolic activity of viable parasites, with delayed imaging enhancing to approximately 90% for detecting active disease. Serological tests detect specific antibodies against E. multilocularis antigens, supporting imaging findings with high specificity. using the Em2 antigen achieves sensitivities of 90-95% for active AE, though cross-reactivity with cystic echinococcosis can occur. confirmation employs antigens like Em18, a 18-kDa band offering over 95% specificity and utility in monitoring treatment response by tracking antibody decline. Recombinant Em18-based immunochromatographic tests provide rapid results with comparable sensitivity for field use. Biopsy is reserved for ambiguous cases, involving histopathological examination of lesions to identify the characteristic PAS-positive acellular laminated layer and, occasionally, protoscolices or germinal epithelium, confirming the diagnosis. Polymerase chain reaction (PCR) on biopsy or fluid samples detects E. multilocularis DNA with sensitivities of 70-90%, enabling species-specific identification even in low-burden infections. Metagenomic next-generation sequencing emerges as a sensitive molecular tool, detecting parasite cell-free DNA in plasma from preoperative patients. Recent 2025 reviews highlight advances in these techniques, including enhanced metagenomic sequencing for improved early detection. Differential diagnosis primarily distinguishes AE from primary , , or , as the infiltrative growth and can closely resemble these malignancies on . Challenges include reduced serological sensitivity (below 80%) in early-stage or extrahepatic disease, potential false negatives in immunosuppressed individuals, and the need for integrated multimodal assessment to avoid misdiagnosis as tumor.

Disease staging

The primary staging system for alveolar echinococcosis (AE), caused by Echinococcus multilocularis, is the PNM classification developed by the Informal Working Group on Echinococcosis (WHO-IWGE). This system assesses the extent of parasitic involvement using three components: P for the location and extent of the parasitic mass in the liver, N for involvement of neighboring organs or structures, and M for the presence of metastases. It relies on imaging modalities such as , computed tomography (CT), and (MRI) to categorize disease progression and guide management. The P category describes the hepatic : P0 indicates no detectable ; P1 refers to localized peripheral lesions without involvement of proximal vessels or ducts; P2 involves central or more extensive lesions with limited proximal vascular or biliary involvement in one lobe; P3 denotes extensive central lesions affecting the hepatic hilum or both lobes; and P4 signifies any with intrahepatic along vessels or the biliary tree. The N category evaluates adjacent structures: N0 means no involvement of neighboring organs, while N1 indicates extension to contiguous sites such as the , , or . The M category addresses distant : M0 denotes no metastases, and M1 confirms distant metastases, typically to the lungs, , or bones.
ComponentSubcategoryDescription
P (Parasitic mass in liver)P0No detectable
P1Peripheral (s) without proximal vascular/biliary involvement
P2Central (s) ≤ 10 cm with proximal vascular/biliary involvement of one lobe
P3Central (s) > 10 cm with hilar involvement of one or both lobes or two
P4Any with extension along vessels into at least two liver lobes
N (Neighboring structures)N0No involvement
N1Involvement of adjacent organs/tissues (e.g., bile ducts, vessels, )
M (Metastases)M0No metastasis
M1Distant metastasis (e.g., , , , )
These components combine into overall stages: stage I (P1 N0 M0) represents limited, localized disease; stage II (P2 N0 M0) indicates moderate central involvement; stage IIIa (P3 N0 M0) and IIIb (P1-4 N1 M0 or P4 N0 M0) denote advanced intrahepatic or regional extension; and stage IV (any P/N with M1) signifies metastatic disease. Ultrasound staging complements the PNM system by classifying AE lesions based on echogenic patterns to differentiate active, transitional, and inactive stages. The multilocularis Ulm Classification- (EMUC-US) defines five types: A1 and A2 for active lesions with vital parasitic tissue; A3 for transitional forms with partial ; and A4 and A5 for inactive, calcified lesions. This helps assess disease activity beyond mere extent. The PNM staging informs treatment decisions, such as determining resectability for curative in early stages (I-II) versus palliative approaches like long-term anti-parasitic or in advanced stages (III-IV). It also aids in standardizing international comparisons of outcomes. Prognostic factors include the stage at , with a 2025 analysis of 334 patients finding that early curative improves overall (hazard 0.48–0.49) but not alveolar echinococcosis-specific ; relative decreases steadily after 5 years post-, primarily influenced by patient age at (younger patients have higher ratios). Historical data from treated cohorts indicate overall 10-year rates of approximately 90%, though outcomes worsen with advanced , older age, lesion location (e.g., hilar involvement), and comorbidities affecting surgical candidacy. Refinements to the PNM system since 2020 have integrated advanced imaging like 18F-fluorodeoxyglucose (FDG-PET)/ to better evaluate metabolic activity and microvascular invasion, enhancing accuracy in staging and prognosis assessment.

Treatment

Treatment of alveolar (AE) caused by Echinococcus multilocularis typically involves a multimodal approach combining , long-term antiparasitic , and supportive measures, with the goal of achieving in early cases or prolonging survival and improving in advanced disease. remains the only potentially curative option when feasible, while drugs are essential for inoperable cases or as adjunct therapy. A 2025 analysis confirmed that early curative improves overall survival but does not significantly affect AE-specific survival. Surgical intervention aims for radical resection to remove all parasitic tissue, which is curative if performed early and achieves R0 status (complete resection with negative margins). In advanced cases with extensive liver involvement or decompensated , orthotopic liver transplantation may be considered, though it carries risks of recurrence and requires lifelong . Major hepatectomies, including trisectionectomies, are often necessary, with additional procedures like vascular reconstruction or to address infiltrative growth patterns. The cornerstone of medical therapy is antiparasitic drugs, primarily administered at 10-15 mg/kg/day in divided doses, often for lifelong duration in unresectable cases to inhibit parasite proliferation and induce partial remission. serves as an alternative at similar doses, though it may have lower . These agents halt or slow growth in the majority of patients, with long-term use increasing 15-year survival rates to 53-80%. Post-surgical with is recommended for at least 2 years to reduce recurrence risk. Puncture-aspiration-injection-reaspiration (PAIR) has limited application in AE due to the multilocular, infiltrative nature of the lesions, which contrasts with the unilocular cysts of cystic echinococcosis; it is rarely used and typically combined with only in select accessible cases. Supportive care includes biliary drainage via endoscopic stenting or sclerosis for complications like cholangitis, and interventions to manage cysts or abscesses in non-surgical candidates. For rare metastatic spread or secondary bacterial infections, additional may be required. With combined treatment, 5-year survival rates range from 70-97%, depending on resectability and , with 10-year rates around 73-94% for surgical and , respectively; ongoing via serial (e.g., or MRI) and is essential to detect progression or recurrence. Challenges include high recurrence rates of 2-30% even after R0 resection, often due to microscopic residual parasites, and drug-related side effects such as and , necessitating regular and potential dose adjustments.

Epidemiology and control

Global distribution

Echinococcus multilocularis is endemic exclusively to the , with established presence in parts of , , and . In Europe, the parasite is highly prevalent in central regions including , , , and , where it has been a longstanding concern in the areas. Expansion has been observed into eastern and southern , with recent detections in the northern Apennines of indicating southward movement. In , major endemic foci exist in , particularly the Qinghai-Tibet Plateau, as well as in and northern . North American distribution centers on , , and the north-central , spanning 13 contiguous states. Emerging areas include southern Europe, where the parasite has been recorded in foxes and jackals in Serbia, and urban environments with increasing fox populations in cities across central Europe. In North America, 2025 reports highlight ongoing spread in Alberta, Canada, particularly among urban coyotes, alongside detections in Washington state. In 2025, the parasite was also detected in Prince Edward Island, marking its presence in a tenth province/territory. Zoonotic hotspots are primarily rural areas with high densities of red foxes as definitive hosts, and climate change is contributing to range expansion by altering suitable habitats for intermediate rodent hosts. The parasite remains rare or absent in Africa, South America, and Australia, which are non-endemic continents for E. multilocularis. Historically, E. multilocularis was first recognized in during the 1980s, initially confined to France, , , and before spreading eastward. In , significant detections and expansions occurred in the 1990s, building on earlier reports from Alaska's zones to the north-central regions. Recent assessments as of 2025 confirm continued range broadening in from five to nine provinces and territories.

Prevalence and incidence

Alveolar echinococcosis, caused by Echinococcus multilocularis, imposes a significant burden, with an estimated median of 10,489 new cases annually (range: 8,191–14,409) according to 2025 modeling, though actual figures may be higher due to underreporting, particularly in endemic Asian regions where is limited. The disease's incidence is concentrated in the , with accounting for over 90% of cases, while and contribute less than 5% combined. In , the mean annual incidence from 1997 to 2023 was 0.063 cases per 100,000 population (0.63 per million), equating to approximately 500–1,000 cases yearly across the continent, with 4,207 cases documented in a of 28 countries. The European Food Safety Authority's 2025 surveillance reported 929 confirmed human cases in the for 2023, at a notification rate of 0.21 per 100,000, indicating stability in core endemic areas like , , , and , but emergence and rises in peripheral regions such as , , and . North American incidence remains low at under 1 case per million population annually, with reporting an annual incidence rate of 0.007 per 100,000 (0.07 per million) and 1–4 new cases per year; around 30 cases have been documented in since 2000, primarily in western provinces like and , often linked to local wildlife cycles. , cases are rare, with only sporadic autochthonous infections reported. Asia bears the highest burden, particularly in , where the national annual incidence is approximately 0.7 per 100,000 (7 per million), yielding about 9,643 cases yearly, though underreporting is prevalent in rural and remote areas. On the , prevalence is markedly elevated, reaching 1.55% in Province and 2.03% in Sichuan's communities, with hotspots like the Tibetan Autonomous Region showing some of the world's highest rates due to close human-livestock-wildlife interfaces; studies highlight multiple strains circulating in these endemic zones. High-risk groups for alveolar echinococcosis include farmers and herders (odds ratio 4.50 and 2.20, respectively), hunters or those handling foxes (odds ratio 2.27), and dog owners (odds ratio 2.50), owing to increased exposure to contaminated environments and animal feces. The disease predominantly affects individuals aged 40–60 years, with a female predominance (odds ratio 1.66), likely reflecting occupational and behavioral patterns in endemic rural settings. Epidemiological trends indicate an overall increase in alveolar echinococcosis cases, driven by expanding populations as definitive hosts following rabies control and habitat changes from , which bring closer to human settlements. In , 2025 data from and reviews suggest a 10–20% rise in incidence over recent decades, with the disease emerging in previously low-risk areas due to these ecological shifts.

Prevention measures

Preventing transmission of Echinococcus multilocularis requires a multifaceted approach targeting the fecal-oral route, primarily through , animal management, and environmental interventions. Individuals in endemic areas should prioritize handwashing with and warm for at least 15-20 seconds after handling pets, soil, or , and before preparing or eating , to minimize of infective eggs shed in or . Children should be educated on these practices, as they are at higher risk due to behaviors like playing in contaminated . Additionally, avoiding direct contact with or wild dog and washing fruits and thoroughly can further reduce exposure. For pet owners, regular deworming of (and cats in endemic regions) with is essential, administered every 1-3 months to prevent them from becoming definitive hosts and shedding eggs. Owners should also confine to leashed or fenced areas to limit scavenging of infected , the primary intermediate hosts, and avoid feeding them raw wild game or that could contain larvae. Veterinary check-ups, including fecal exams, support these measures by detecting infections early. At the level, of populations, particularly red foxes, is critical for monitoring prevalence and guiding interventions. In the , annual assessments under Commission Delegated Regulation (EU) 2018/772, as evaluated by the in 2025, ensure of foxes to track E. multilocularis and inform efforts. Baiting programs delivering to foxes have proven effective; monthly over extended periods significantly reduces egg contamination in the , with long-term studies showing sustained in mixed rural-urban settings. Environmental disinfection of eggs is challenging due to their —they survive freezing at -20°C for months and resist many commercial disinfectants—but heating above 60°C for at least 3 minutes or freezing at -70°C for 4 days can inactivate them on contaminated surfaces or water sources. Rodent in endemic areas, such as reducing vole populations through habitat management, is less effective as a standalone compared to targeting definitive hosts. Education campaigns in high-risk communities emphasize , pet deworming, and avoiding wildlife contact, often integrated with initiatives. In hyperendemic regions like the Tibetan Autonomous Region of China, mass screening using and has been implemented since 2006, identifying cases early and supporting targeted interventions that reduced human prevalence from 7.9% in 2002 to lower levels by 2021. Key challenges include the difficulty of eradicating the wildlife reservoir, as foxes and rodents are abundant and mobile, making complete elimination impractical on a large scale. exacerbates this by potentially expanding suitable habitats northward and to higher elevations, increasing transmission risk through altered host distributions. Adaptive measures, such as enhanced in emerging areas, are thus necessary. Deworming programs demonstrate high effectiveness; for instance, regular praziquantel baiting in foxes has reduced environmental egg shedding by over 90% in controlled urban trials, while routine in populations in endemic areas has lowered by 70-80% in some studies, though sustained effort over decades is required for lasting impact.

References

  1. [1]
    DPDx - Echinococcosis - CDC
    Human echinococcosis (hydatidosis, or hydatid disease) is caused by the larval stages of cestodes (tapeworms) of the genus Echinococcus.
  2. [2]
    Echinococcosis - World Health Organization (WHO)
    May 17, 2021 · Human echinococcosis is a parasitic disease caused by tapeworms of the genus Echinococcus. The two most important forms in humans are cystic ...
  3. [3]
  4. [4]
    Taxonomy browser (Echinococcus multilocularis) - NCBI
    Echinococcus multilocularis taxonomy, taxonomy ... classification - please consult the relevant scientific literature for the most reliable information.
  5. [5]
    Taxonomy, phylogeny and molecular epidemiology of Echinococcus ...
    Oct 30, 2015 · Although taxonomic studies have recognised E. multilocularis as a separate entity from the Echinococcus granulosus complex and other members of ...
  6. [6]
    Control of Cystic Echinococcosis/Hydatidosis: 1863–2002
    Batsch named the cystic parasite as Hydatigera granulosa in 1786, and in 1808 Rudolphi introduced the name Echinococcus (spiny berry) probably to describe the ...Missing: etymology | Show results with:etymology
  7. [7]
    Rediscovery of a name-bearing type of Echinococcus multilocularis ...
    The name is based on the 'spiny' roundish protoscoleces found in cysts of Hydatigena granulosa Batsch, 1786, a species which is currently known as Echinococcus ...Missing: etymology | Show results with:etymology
  8. [8]
    A hundred years of controversy about the taxonomic ... - PubMed
    The parasitic diseases which we know today as cystic and alveolar echinococcosis are zoonoses known since antique times, and 1855, respectively.
  9. [9]
    Echinococcosis: Advances in the 21st Century - PubMed Central
    Echinococcosis is a zoonosis caused by cestodes of the genus Echinococcus (family Taeniidae). This serious and near-cosmopolitan disease continues to be a ...<|separator|>
  10. [10]
  11. [11]
    Influence of environmental factors on the infectivity of Echinococcus ...
    Echinococcus eggs survive up to 240 days in autumn/winter, but only 78 in summer. High temperatures and desiccation reduce infectivity. Low temperatures are ...
  12. [12]
    Hepatic Alveolar Hydatid Cyst: A Brief Review of Published Cases ...
    Echinococcus multilocularis is the cause of alveolar hydatid disease, which most commonly involves the liver in more than 90% of cases.
  13. [13]
  14. [14]
    Echinococcus multilocularis - an overview | ScienceDirect Topics
    Alveolar echinococcosis (AE) is a zoonotic cestode infection caused by Echinococcus multilocularis. The disease occurs in the Northern Hemisphere.
  15. [15]
    About Alveolar echinococcosis (AE) - CDC
    Sep 4, 2024 · AE is caused by tumor-like or cyst-like tapeworm larvae growing in the body. AE usually involves the liver but can spread to other organs of the body.
  16. [16]
    Clinical Overview of Echinococcosis - CDC
    May 11, 2024 · Signs and symptoms may include hepatic enlargement with or without a palpable mass in the right upper quadrant, right epigastric pain, nausea, ...Missing: authoritative | Show results with:authoritative
  17. [17]
    Echinococcosis - Infectious Diseases - MSD Manuals
    Oncospheres penetrate the intestinal wall, migrate via the circulation, and lodge in the liver or lungs or, less frequently, in the brain, bone, or other organs ...
  18. [18]
    Hepatobiliary complications of alveolar echinococcosis: A long-term ...
    Complications such as biliary obstruction, portal hypertension, and bleeding esophageal varices have been described in advanced disease stages and are ascribed ...
  19. [19]
    Comprehensive Survival Analysis of Alveolar Echinococcosis ... - CDC
    Apr 22, 2025 · Before benzimidazole drug therapy, 10-year death rates were 90% without surgical resection. In unresectable patients, long-term benzimidazole ...
  20. [20]
    Late biliary complications in human alveolar echinococcosis are ...
    In another scenario, the altered bile duct anatomy after AE infiltration might promote secondary infections or duodenal reflux causing secondary inflammation ...
  21. [21]
  22. [22]
    Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis
    This review summarizes the latest diagnostic methods for AE, focusing on serological tests and imaging techniques such as ultrasonography (US), computed ...<|control11|><|separator|>
  23. [23]
    Comprehensive diagnosis and treatment of alveolar echinococcosis
    The 5-year and 10-year survival rates were 96.9% and 90.6%, respectively. 69 of all patients under treatment experienced progression of residual lesions or ...
  24. [24]
    WHO classification of alveolar echinococcosis: principles ... - PubMed
    A clinical classification for alveolar echinococcosis. It was designated as PNM system (P = parasitic mass in the liver, N = involvement of neighbouring organs ...
  25. [25]
    Echinococcosis: Advances in the 21st Century - ASM Journals
    Feb 13, 2019 · TABLE 2 WHO Informal Working Group on Echinococcosis PNM classification and staging of alveolar echinococcosis. Classification, Description. P ...
  26. [26]
    Echinococcosis multilocularis Ulm classification-ultrasound - PubMed
    Nov 21, 2015 · To establish an ultrasonographic classification based on a large sample of patients with confirmed hepatic alveolar echinococcosis (AE).
  27. [27]
    Treatment of Complicated Hepatic Alveolar Echinococcosis Disease ...
    Mar 23, 2022 · This article reports a clinical case of a complex HAE treated by the surgical method of “middle liver resection + abdominal enlarged lymph node resection + ...
  28. [28]
    Current status of diagnosis and treatment of hepatic echinococcosis
    Core tip: Echinococcus granulosus and Echinococcus multilocularis infections are the most common parasitic diseases of the liver. They could be asymptomatic for ...
  29. [29]
    Alveolar Echinococcosis—A Challenging Task for the Hepatobiliary ...
    Dec 31, 2021 · Alveolar echinococcosis (AE) is an ultimately fatal disease, whose only curative treatment is surgery. Due to its late presentation extended liver resections ...
  30. [30]
    Current status of drug therapy for alveolar echinococcosis - PMC - NIH
    Benzimidazole compounds, such as albendazole and mebendazole, are the current mainstays of treatment, offering good efficacy. Nevertheless, these medications ...
  31. [31]
    Elevated incidence of alveolar echinococcosis in ... - PubMed
    May 31, 2019 · Survival at 5 and 10 years after surgery was 97% and 94%, respectively, and after conservative treatment 91% and 73%, respectively. Curative ...
  32. [32]
    Surgical treatment strategies for hepatic alveolar echinococcosis
    Apr 5, 2019 · Reported recurrence rates after curative resection are between 2% and 16% at 5–20 years (Table 1). Recurrence usually occurs at the site of ...<|control11|><|separator|>
  33. [33]
    Human alveolar echinococcosis–global, regional, and national ...
    E. multilocularis is endemic exclusively in the Northern Hemisphere, including continental Europe, Asia, and North America, with China inferred to account for ...
  34. [34]
    Annual assessment of Echinococcus multilocularis surveillance ...
    Jul 24, 2025 · This report comprises the 15th assessment of the Echinococcus multilocularis surveillance scientific reports, provided by Finland, Ireland, ...
  35. [35]
    Transmission ecosystems of Echinococcus multilocularis in China ...
    Since the late 80s, a number of hotspots have been identified in continental Asia, mostly in China, wherein the ecology of intermediate host communities has ...
  36. [36]
  37. [37]
    Echinococcus multilocularis in North America: the great unknown
    In our review, we present the available data on E. multilocularis infections in wild and domestic animals and humans in North America and emphasize the lack of ...
  38. [38]
    Global and local drivers of Echinococcus multilocularis infection in ...
    Dec 1, 2023 · The cestode, Echinococcus multilocularis, is one of the most threatening parasitic challenges in the European Union.Missing: Scandinavia | Show results with:Scandinavia
  39. [39]
    Tracking the spread of a deadly parasite in North America - DVM360
    Jun 19, 2025 · A session at the 2025 ACVIM Forum covered cases of echinococcus multilocularis and its expanding presence in North America, highlighting the ...
  40. [40]
    Detection of Echinococcus multilocularis in coyotes in Washington ...
    Aug 27, 2025 · One such parasite is Echinococcus multilocularis, a small tapeworm of canids that can cause a severe, life-threatening disease in humans ...Missing: etymology | Show results with:etymology
  41. [41]
    The geographical distribution and prevalence of Echinococcus ...
    Sep 28, 2016 · This study aimed to provide a systematic review on the geographical distribution of Echinococcus multilocularis in definitive and intermediate hosts in the ...<|separator|>
  42. [42]
    Presence of Echinococcus eggs in the environment and food
    While not systematically testing for E. multilocularis may be justified on non-endemic continents (i.e. Africa and South America), it would appear to be of ...
  43. [43]
    Echinococcus multilocularis: An Emerging Pathogen in Hungary and ...
    Mar 3, 2003 · This parasite may be spreading eastward because the population of foxes has increased because of human interventions, and this spread may result ...Missing: climate | Show results with:climate
  44. [44]
    Changing distribution, diversity, and health impact of Echinococcus ...
    Alveolar echinococcosis (AE) caused by Echinococcus multilocularis is a rare but serious animal and human disease in the northern hemisphere.
  45. [45]
    The Global Burden of Alveolar Echinococcosis - PMC
    Jun 22, 2010 · Our studies suggest that AE results in a median of 18,235 cases globally with a burden of 666,433 DALYs per annum. ... The purpose of this study ...
  46. [46]
  47. [47]
    Prevalence of human alveolar echinococcosis in China
    The meta-analysis indicated that the pooled HAE prevalence in China was 0.96% (95% CI: 0.71 to 1.25%). Factors potentially influencing HAE prevalence were ...
  48. [48]
    Potential risk factors associated with human alveolar echinococcosis
    In the cross-sectional studies, the following PRFs showed higher odds of outcome: “dog ownership”, “play with dogs”, “gender: female”, “age over 20 years”, “ ...
  49. [49]
    Preventing Echinococcosis - CDC
    Jun 24, 2024 · Wash your hands with soap and warm water after handling dogs, and before handling food. Teach children the importance of washing hands to ...Missing: personal | Show results with:personal
  50. [50]
    Echinococcus multilocularis infection | The Windsor-Essex County ...
    Wash your hands often for at least 15 seconds with warm water and soap, especially before and after preparing foods, before eating, and after handling pets and ...
  51. [51]
    Echinococcus spp - Companion Animal Parasite Council
    Feb 7, 2025 · multilocularis is typically maintained in a sylvatic cycle with foxes as definitive hosts and smaller mammals, such as rodents, as intermediate ...
  52. [52]
    Echinococcus multilocularis - Kentucky Department of Fish & Wildlife
    Jun 14, 2024 · Canids, such as red and gray foxes, coyotes, and domestic dogs serve as definitive hosts in the parasite's life cycle. This is a zoonotic ...
  53. [53]
    Echinococcosis in Dogs | VCA Animal Hospitals
    The best way to prevent echinococcosis is to prevent your dog from roaming and ingesting live or dead rodents. It is also important to limit your dog's exposure ...
  54. [54]
    Annual assessment of Echinococcus multilocularis surveillance ...
    Jul 24, 2025 · Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2025 in the context of Commission Delegated Regulation (EU) ...Missing: alveolar | Show results with:alveolar
  55. [55]
    Control Strategy for Echinococcus multilocularis - PMC
    Trimonthly baiting intervals were far less effective and did not prevent parasite recovery. Keywords: Control, Echinococcus multilocularis, praziquantel, ...
  56. [56]
    Assessment of echinococcosis control in Tibet Autonomous Region ...
    May 26, 2022 · The Plan requires complete screening on all populations and implementation of various control measures (focusing on infection source control).
  57. [57]
    Divergent impacts of warming weather on wildlife disease risk ...
    Nov 20, 2020 · As climate change accelerates, wildlife hosts adapted to cooler or milder climates may suffer increasing risk of infectious disease outbreaks, ...
  58. [58]
    Anthelmintic Baiting of Foxes against Urban Contamination with ...
    This controlled baiting study shows that a pronounced reduction of E. multilocularis egg contamination is feasible in urban areas where the organism is highly ...<|control11|><|separator|>
  59. [59]
    Effective long-term control of Echinococcus multilocularis in a mixed ...
    Apr 12, 2019 · In this study we confirmed the effectiveness of anthelmintic praziquantel treatment of foxes in a mixed urban-rural area of southern Germany.